Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

C Cerrato, F Di Raimondo, L de Paoli, S Spada, F Patriarca, C Crippa, R Mina, T Guglielmelli, D Ben-Yehuda, D Oddolo, C Nozzoli, E Angelucci, N Cascavilla, R Rizzi, S Rocco, L Baldini, E Ponticelli, M Marcatti, C Cangialosi, T Caravita & 11 others G Benevolo, R Ria, A Nagler, P Musto, P Tacchetti, P Corradini, M Offidani, A Palumbo, MT Petrucci, M Boccadoro, F Gay

Research output: Contribution to journalArticle

Abstract

Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and RV-MM-PI-209). Methods: Primary endpoints were progression-free survival (PFS)1, PFS2 and overall survival (OS) of CR patients randomized to maintenance and no maintenance. Secondary endpoints were PFS1, PFS2 and OS in very good partial response/partial response (VGPR/PR) patients. Results: Overall, 213 patients obtained CR after induction/consolidation, 118 received maintenance and 95 no maintenance. In patients achieving CR, maintenance significantly improved PFS1 (HR 0.50, P < 0.001), PFS2 (HR 0.58, P 0.02) and OS (HR 0.51, P 0.02) compared with no maintenance; the advantage was maintained across all the analyzed subgroups according to age, International Staging System (ISS) stage, cytogenetic profile and treatment. Similar features were seen in VGPR/PR patients. Conclusion: Maintenance prolonged survival in CR and in VGPR/PR patients. The benefit in CR patients suggests the importance of continuing treatment in patients with chemo-sensitive disease. Trial registration: The two source studies are registered at ClinicalTrials.gov: identification numbers NCT01063179 and NCT00551928. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature
Original languageEnglish
Pages (from-to)1357-1366
Number of pages10
JournalJournal of Cancer Research and Clinical Oncology
Volume144
Issue number7
DOIs
Publication statusPublished - 2018

Fingerprint

Maintenance
Survival
Therapeutics
Multiple Myeloma
Cytogenetics
Disease-Free Survival
Germany

Cite this

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. / Cerrato, C; Di Raimondo, F; de Paoli, L; Spada, S; Patriarca, F; Crippa, C; Mina, R; Guglielmelli, T; Ben-Yehuda, D; Oddolo, D; Nozzoli, C; Angelucci, E; Cascavilla, N; Rizzi, R; Rocco, S; Baldini, L; Ponticelli, E; Marcatti, M; Cangialosi, C; Caravita, T; Benevolo, G; Ria, R; Nagler, A; Musto, P; Tacchetti, P; Corradini, P; Offidani, M; Palumbo, A; Petrucci, MT; Boccadoro, M; Gay, F.

In: Journal of Cancer Research and Clinical Oncology, Vol. 144, No. 7, 2018, p. 1357-1366.

Research output: Contribution to journalArticle

Cerrato, C, Di Raimondo, F, de Paoli, L, Spada, S, Patriarca, F, Crippa, C, Mina, R, Guglielmelli, T, Ben-Yehuda, D, Oddolo, D, Nozzoli, C, Angelucci, E, Cascavilla, N, Rizzi, R, Rocco, S, Baldini, L, Ponticelli, E, Marcatti, M, Cangialosi, C, Caravita, T, Benevolo, G, Ria, R, Nagler, A, Musto, P, Tacchetti, P, Corradini, P, Offidani, M, Palumbo, A, Petrucci, MT, Boccadoro, M & Gay, F 2018, 'Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis', Journal of Cancer Research and Clinical Oncology, vol. 144, no. 7, pp. 1357-1366. https://doi.org/10.1007/s00432-018-2641-5
Cerrato, C ; Di Raimondo, F ; de Paoli, L ; Spada, S ; Patriarca, F ; Crippa, C ; Mina, R ; Guglielmelli, T ; Ben-Yehuda, D ; Oddolo, D ; Nozzoli, C ; Angelucci, E ; Cascavilla, N ; Rizzi, R ; Rocco, S ; Baldini, L ; Ponticelli, E ; Marcatti, M ; Cangialosi, C ; Caravita, T ; Benevolo, G ; Ria, R ; Nagler, A ; Musto, P ; Tacchetti, P ; Corradini, P ; Offidani, M ; Palumbo, A ; Petrucci, MT ; Boccadoro, M ; Gay, F. / Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. In: Journal of Cancer Research and Clinical Oncology. 2018 ; Vol. 144, No. 7. pp. 1357-1366.
@article{1c50a580c27d4955a456db873d98817c,
title = "Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis",
abstract = "Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and RV-MM-PI-209). Methods: Primary endpoints were progression-free survival (PFS)1, PFS2 and overall survival (OS) of CR patients randomized to maintenance and no maintenance. Secondary endpoints were PFS1, PFS2 and OS in very good partial response/partial response (VGPR/PR) patients. Results: Overall, 213 patients obtained CR after induction/consolidation, 118 received maintenance and 95 no maintenance. In patients achieving CR, maintenance significantly improved PFS1 (HR 0.50, P < 0.001), PFS2 (HR 0.58, P 0.02) and OS (HR 0.51, P 0.02) compared with no maintenance; the advantage was maintained across all the analyzed subgroups according to age, International Staging System (ISS) stage, cytogenetic profile and treatment. Similar features were seen in VGPR/PR patients. Conclusion: Maintenance prolonged survival in CR and in VGPR/PR patients. The benefit in CR patients suggests the importance of continuing treatment in patients with chemo-sensitive disease. Trial registration: The two source studies are registered at ClinicalTrials.gov: identification numbers NCT01063179 and NCT00551928. {\circledC} 2018 Springer-Verlag GmbH Germany, part of Springer Nature",
author = "C Cerrato and {Di Raimondo}, F and {de Paoli}, L and S Spada and F Patriarca and C Crippa and R Mina and T Guglielmelli and D Ben-Yehuda and D Oddolo and C Nozzoli and E Angelucci and N Cascavilla and R Rizzi and S Rocco and L Baldini and E Ponticelli and M Marcatti and C Cangialosi and T Caravita and G Benevolo and R Ria and A Nagler and P Musto and P Tacchetti and P Corradini and M Offidani and A Palumbo and MT Petrucci and M Boccadoro and F Gay",
year = "2018",
doi = "10.1007/s00432-018-2641-5",
language = "English",
volume = "144",
pages = "1357--1366",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

AU - Cerrato, C

AU - Di Raimondo, F

AU - de Paoli, L

AU - Spada, S

AU - Patriarca, F

AU - Crippa, C

AU - Mina, R

AU - Guglielmelli, T

AU - Ben-Yehuda, D

AU - Oddolo, D

AU - Nozzoli, C

AU - Angelucci, E

AU - Cascavilla, N

AU - Rizzi, R

AU - Rocco, S

AU - Baldini, L

AU - Ponticelli, E

AU - Marcatti, M

AU - Cangialosi, C

AU - Caravita, T

AU - Benevolo, G

AU - Ria, R

AU - Nagler, A

AU - Musto, P

AU - Tacchetti, P

AU - Corradini, P

AU - Offidani, M

AU - Palumbo, A

AU - Petrucci, MT

AU - Boccadoro, M

AU - Gay, F

PY - 2018

Y1 - 2018

N2 - Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and RV-MM-PI-209). Methods: Primary endpoints were progression-free survival (PFS)1, PFS2 and overall survival (OS) of CR patients randomized to maintenance and no maintenance. Secondary endpoints were PFS1, PFS2 and OS in very good partial response/partial response (VGPR/PR) patients. Results: Overall, 213 patients obtained CR after induction/consolidation, 118 received maintenance and 95 no maintenance. In patients achieving CR, maintenance significantly improved PFS1 (HR 0.50, P < 0.001), PFS2 (HR 0.58, P 0.02) and OS (HR 0.51, P 0.02) compared with no maintenance; the advantage was maintained across all the analyzed subgroups according to age, International Staging System (ISS) stage, cytogenetic profile and treatment. Similar features were seen in VGPR/PR patients. Conclusion: Maintenance prolonged survival in CR and in VGPR/PR patients. The benefit in CR patients suggests the importance of continuing treatment in patients with chemo-sensitive disease. Trial registration: The two source studies are registered at ClinicalTrials.gov: identification numbers NCT01063179 and NCT00551928. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature

AB - Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and RV-MM-PI-209). Methods: Primary endpoints were progression-free survival (PFS)1, PFS2 and overall survival (OS) of CR patients randomized to maintenance and no maintenance. Secondary endpoints were PFS1, PFS2 and OS in very good partial response/partial response (VGPR/PR) patients. Results: Overall, 213 patients obtained CR after induction/consolidation, 118 received maintenance and 95 no maintenance. In patients achieving CR, maintenance significantly improved PFS1 (HR 0.50, P < 0.001), PFS2 (HR 0.58, P 0.02) and OS (HR 0.51, P 0.02) compared with no maintenance; the advantage was maintained across all the analyzed subgroups according to age, International Staging System (ISS) stage, cytogenetic profile and treatment. Similar features were seen in VGPR/PR patients. Conclusion: Maintenance prolonged survival in CR and in VGPR/PR patients. The benefit in CR patients suggests the importance of continuing treatment in patients with chemo-sensitive disease. Trial registration: The two source studies are registered at ClinicalTrials.gov: identification numbers NCT01063179 and NCT00551928. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature

U2 - 10.1007/s00432-018-2641-5

DO - 10.1007/s00432-018-2641-5

M3 - Article

VL - 144

SP - 1357

EP - 1366

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -